
## **Gilles** Dietrich

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3464286/publications.pdf Version: 2024-02-01



CILLES DIFTRICH

#	Article	IF	CITATIONS
1	Delta opioid receptors on nociceptive sensory neurons mediate peripheral endogenous analgesia in colitis. Journal of Neuroinflammation, 2022, 19, 7.	7.2	6
2	Identification of new enterosynes using prebiotics: roles of bioactive lipids and mu-opioid receptor signalling in humans and mice. Gut, 2021, 70, 1078-1087.	12.1	28
3	Analgesic Effects of Topical Amitriptyline in Patients With Chemotherapy-Induced Peripheral Neuropathy: Mechanistic Insights From Studies in Mice. Journal of Pain, 2021, 22, 440-453.	1.4	6
4	Bacteria-derived long chain fatty acid exhibits anti-inflammatory properties in colitis. Gut, 2021, 70, 1088-1097.	12.1	105
5	Endothelin-1 Exhibiting Pro-Nociceptive and Pro-Peristaltic Activities Is Increased in Peritoneal Carcinomatosis. Frontiers in Pain Research, 2021, 2, 613187.	2.0	1
6	Colitis Linked to Endoplasmic Reticulum Stress Induces Trypsin Activity Affecting Epithelial Functions. Journal of Crohn's and Colitis, 2021, 15, 1528-1541.	1.3	5
7	Pain Management in a Model of Interstitial Cystitis/Bladder Pain Syndrome by a Vaccinal Strategy. Frontiers in Pain Research, 2021, 2, 642706.	2.0	5
8	Peripheral Opioid Receptor Blockade Enhances Epithelial Damage in Piroxicam-Accelerated Colitis in IL-10-Deficient Mice. International Journal of Molecular Sciences, 2021, 22, 7387.	4.1	6
9	Endogenous control of inflammatory visceral pain by T cellâ€derived opioids in ILâ€10â€deficient mice. Neurogastroenterology and Motility, 2020, 32, e13743.	3.0	13
10	Pharmacological insight into the activation of the human neuropeptide FF2 receptor. Peptides, 2020, 134, 170406.	2.4	1
11	Polyunsaturated fatty acid metabolites: biosynthesis in Leishmania and role in parasite/host interaction. Journal of Lipid Research, 2019, 60, 636-647.	4.2	20
12	T-lymphocyte-derived enkephalins reduce Th1/Th17 colitis and associated pain in mice. Journal of Gastroenterology, 2018, 53, 215-226.	5.1	26
13	Mobilization of CD4+ T lymphocytes in inflamed mucosa reduces pain in colitis mice: toward a vaccinal strategy to alleviate inflammatory visceral pain. Pain, 2018, 159, 331-341.	4.2	22
14	5-oxoETE triggers nociception in constipation-predominant irritable bowel syndrome through MAS-related G protein–coupled receptor D. Science Signaling, 2018, 11, .	3.6	44
15	Inflammation and Gut-Brain Axis During Type 2 Diabetes: Focus on the Crosstalk Between Intestinal Immune Cells and Enteric Nervous System. Frontiers in Neuroscience, 2018, 12, 725.	2.8	39
16	Identification of an analgesic lipopeptide produced by the probiotic Escherichia coli strain Nissle 1917. Nature Communications, 2017, 8, 1314.	12.8	86
17	Mu and delta opioid receptor knockout mice show increased colonic sensitivity. European Journal of Pain, 2017, 21, 623-634.	2.8	17
18	Nod2: The intestinal gate keeper. PLoS Pathogens, 2017, 13, e1006177.	4.7	119

**GILLES DIETRICH** 

#	Article	IF	CITATIONS
19	Endogenous analgesia mediated by CD4+ T lymphocytes is dependent on enkephalins in mice. Journal of Neuroinflammation, 2016, 13, 132.	7.2	40
20	Intestinal inflammation and pain management. Current Opinion in Pharmacology, 2015, 25, 50-55.	3.5	21
21	TRPV1 sensitization mediates postinflammatory visceral pain following acute colitis. American Journal of Physiology - Renal Physiology, 2015, 309, G87-G99.	3.4	92
22	Endogenous Regulation of Visceral Pain via Production of Opioids by Colitogenic CD4+ T Cells in Mice. Gastroenterology, 2014, 146, 166-175.	1.3	80
23	Endogenous Regulation of Inflammatory Pain by T-cell-derived Opioids. Inflammatory Bowel Diseases, 2014, 20, 1870-1877.	1.9	13
24	Essential fatty acids deficiency promotes lipogenic gene expression and hepatic steatosis through the liver X receptor. Journal of Hepatology, 2013, 58, 984-992.	3.7	41
25	Food-Grade Bacteria Expressing Elafin Protect Against Inflammation and Restore Colon Homeostasis. Science Translational Medicine, 2012, 4, 158ra144.	12.4	198
26	Denatured G-Protein Coupled Receptors as Immunogens to Generate Highly Specific Antibodies. PLoS ONE, 2012, 7, e46348.	2.5	12
27	Immune conditions associated with CD4+ T effector-induced opioid release and analgesia. Pain, 2012, 153, 485-493.	4.2	43
28	Endogenous Opioid-Mediated Analgesia Is Dependent on Adaptive T Cell Response in Mice. Journal of Immunology, 2011, 186, 5078-5084.	0.8	60
29	PGE2 inhibits natural killer and Î <sup>3</sup> δT cell cytotoxicity triggered by NKR and TCR through a cAMP-mediated PKA type I-dependent signaling. Biochemical Pharmacology, 2010, 80, 838-845.	4.4	108
30	μ-Opioid Receptor Is Induced by IL-13 within Lymph Nodes from Patients with Sézary Syndrome. Journal of Investigative Dermatology, 2010, 130, 1337-1344.	0.7	20
31	Thrombin receptor: An endogenous inhibitor of inflammatory pain, activating opioid pathways. Pain, 2009, 146, 121-129.	4.2	42
32	A regulatory crossâ€ŧalk between Vγ9Vδ2 T lymphocytes and mesenchymal stem cells. European Journal of Immunology, 2009, 39, 752-762.	2.9	85
33	Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases. Clinical and Experimental Immunology, 2008, 86, 192-198.	2.6	117
34	Delta opioid receptors mediate chemotaxis in bone marrow-derived dendritic cells. Journal of Neuroimmunology, 2008, 197, 21-28.	2.3	33
35	Opioid receptor blockade increases the number of lymphocytes without altering T cell response in draining lymph nodes in vivo. Journal of Neuroimmunology, 2007, 188, 95-102.	2.3	21
36	The cGMP/Protein Kinase G Pathway Contributes to Dihydropyridine-sensitive Calcium Response and Cytokine Production in TH2 Lymphocytes. Journal of Biological Chemistry, 2006, 281, 12421-12427.	3.4	27

**GILLES DIETRICH** 

#	Article	IF	CITATIONS
37	Opioid receptor blockade reduces Fas-induced hepatitis in mice. Hepatology, 2004, 40, 1136-1143.	7.3	36
38	Anti-μ-opioid-receptor IgG antibodies are commonly present in serum from healthy blood donors: evidence for a role in apoptotic immune cell death. Blood, 2002, 100, 3261-3268.	1.4	13
39	Implication of the First and Third Extracellular Loops of the μ-Opioid Receptor in the Formation of the Ligand Binding Site: A Study Using Chimeric μ-Opioid/Angiotensin Receptors. Journal of Neurochemistry, 2002, 70, 2106-2111.	3.9	13
40	Identification of μ-Opioid Receptor Epitopes Recognized by Agonistic IgG. Biochemical and Biophysical Research Communications, 2001, 280, 1142-1147.	2.1	2
41	Morphine-like Activity of Natural Human IgG Autoantibodies Is because of Binding to the First and Third Extracellular Loops of the μ-Opioid Receptor. Journal of Biological Chemistry, 1999, 274, 20079-20082.	3.4	17
42	Isolation and characterization of natural human IgG with a morphine-like activity. European Journal of Immunology, 1999, 29, 997-1003.	2.9	13
43	Non-immunoglobulin serum proteins prevent the binding of IgG from normal rats and from rats with Th2-mediated autoimmune glomerulonephritis to various autoantigens including glomerular antigens. European Journal of Immunology, 1998, 28, 183-192.	2.9	18
44	Non-immunoglobulin serum proteins prevent the binding of IgG from normal rats and from rats with Th2-mediated autoimmune glomerulonephritis to various autoantigens including glomerular antigens. European Journal of Immunology, 1998, 28, 183-192.	2.9	1
45	Identification in the μ-opioid receptor of cysteine residues responsible for inactivation of ligand binding by thiol alkylating and reducing agents. FEBS Letters, 1997, 408, 135-140.	2.8	20
46	Variable Region-Connected, Dimeric Fraction of Intravenous Immunoglobulin Enriched in Natural Autoantibodies. Journal of Autoimmunity, 1995, 8, 405-413.	6.5	35
47	V Region-Mediated Selection of Autoreactive Repertoires by Intravenous Immunoglobulin (i.v.lg). Immunological Reviews, 1994, 139, 79-107.	6.0	158
48	Anti-CD4 activity of normal human immunoglobulin G for therapeutic use. (Intravenous) Tj ETQq0 0 0 rgBT /Over	lock 10 Tf 0.4	50 302 Td (i
49	The use of intravenous immunoglobulins in the treatment of factor VIII inhibitors. Seminars in Hematology, 1994, 31, 65-6.	3.4	8
50	Selection of the expressed B cell repertoire by infusion of normal immunoglobulin G in a patient with autoimmune thyroiditis. European Journal of Immunology, 1993, 23, 2945-2950.	2.9	51
51	Polyreactivity is a Property of Natural and Disease-Associated Human Autoantibodies. Scandinavian Journal of Immunology, 1993, 38, 190-196.	2.7	57
52	Age-related Changes in Specificity of Human Natural Autoantibodies to Thyroglobulin. Journal of Autoimmunity, 1993, 6, 639-648.	6.5	14
53	Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 3795-3799.	7.1	138

<sup>54</sup>Modulation of autoimmunity by intravenous immune globulin through interaction with the function<br/>of the immune/idiotypic network. Clinical Immunology and Immunopathology, 1992, 62, S73-S81.2.095

**GILLES DIETRICH** 

#	Article	IF	CITATIONS
55	A V region-connected autoreactive subfraction of normal human serum immunoglobulin G. European Journal of Immunology, 1992, 22, 1701-1706.	2.9	53
56	Idiotypic modulation of autoimmunity by therapeutic human immunoglobulin preparations (IVIg). Advances in Nephrology From the Necker Hospital, 1992, 21, 329-46.	0.2	1
57	Population dynamics of natural antibodies in normal and autoimmune individuals Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 5917-5921.	7.1	84
58	Intravenous immunoglobulin in the treatment of spontaneously acquired factor VIII:C inhibitors. American Journal of Medicine, 1991, 91, S35-S39.	1.5	45
59	Evidence for a restricted idiotypic and epitopic specificity of anti-thyroglobulin autoantibodies in patients with autoimmune thyroiditis. European Journal of Immunology, 1991, 21, 811-814.	2.9	35
60	A monoclonal anti-idiotypic antibody against the antigen-combining site of anti-factor VIII autoantibodies defines an idiotope that is recognized by normal human polyspecific immunoglobulins for therapeutic use (IVIg). Journal of Autoimmunity, 1990, 3, 547-557.	6.5	34
61	Normal immunoglobulin G (IgG) for therapeutic use (intravenous Ig) contain antiidiotypic specificities against an immunodominant, disease-associated, cross-reactive idiotype of human anti-thyroglobulin autoantibodies Journal of Clinical Investigation, 1990, 85, 620-625.	8.2	141
62	Antiâ€idiotypes against Autoantibodies in Normal Immunoglobulins: Evidence for Network Regulation of Human Autoimmune Responses. Immunological Reviews, 1989, 110, 135-149.	6.0	183
63	Antiidiotypic suppression of autoantibodies with normal polyspecific immunoglobulins. Research in Immunology, 1989, 140, 19-31.	0.9	30